Medical Editor: John P. Cunha, DO, FACOEP
Ga 68 DOTATOC Injection is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. Common side effects of Ga 68 DOTATOC include:
- itching, and
The recommended dose of Ga 68 DOTATOC Injection for adults is 148 MBq (4 mCi) as a bolus intravenous injection. The recommended dose of Ga 68 DOTATOC Injection for pediatric patients is 1.59 MBq/kg (0.043 mCi/kg) with a range of 11.1 MBq (0.3 mCi) to 111 MBq (3 mCi), as a bolus intravenous injection. Ga 68 DOTATOC may interact with short-acting somatostatin analogs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Ga 68 DOTATOC; it is unknown how it would affect a fetus. It is unknown if Ga 68 DOTATOC passes into breast milk. Breast milk should be pumped and discarded for 8 hours after administration of Ga 68 DOTATOC. Consult your doctor before breastfeeding.
Our Ga 68 DOTATOC Injection, for Intravenous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of Ga-68 DOTATOC injection was evaluated in 334 patients in clinical trials of patients receiving a single dose of Ga-68 DOTATOC injection for imaging known or suspected NET.
The following adverse reactions occurred at a rate of < 2%:
Gastrointestinal Disorders: nausea
The following adverse reactions occurred at a rate of a < 1%
Skin and Subcutaneous Tissue Disorders: pruritus
Vascular Disorders: flushing
Read the entire FDA prescribing information for Ga 68 DOTATOC (Ga 68 DOTATOC )
© Ga 68 DOTATOC Patient Information is supplied by Cerner Multum, Inc. and Ga 68 DOTATOC Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
Health Solutions From Our Sponsors